nodes	percent_of_prediction	percent_of_DWPC	metapath
Perflutren—Sevoflurane—CYP3A4—bone cancer	0.0263	1	CrCbGaD
Perflutren—Coma—Doxorubicin—bone cancer	0.00457	0.0047	CcSEcCtD
Perflutren—Visual disturbance—Methotrexate—bone cancer	0.00443	0.00455	CcSEcCtD
Perflutren—Muscle spasms—Cisplatin—bone cancer	0.00443	0.00454	CcSEcCtD
Perflutren—Hypertonia—Doxorubicin—bone cancer	0.00439	0.0045	CcSEcCtD
Perflutren—Abnormal vision—Doxorubicin—bone cancer	0.00436	0.00448	CcSEcCtD
Perflutren—Vision blurred—Cisplatin—bone cancer	0.00434	0.00446	CcSEcCtD
Perflutren—Anaphylactoid reaction—Methotrexate—bone cancer	0.00433	0.00445	CcSEcCtD
Perflutren—Cardiac failure congestive—Epirubicin—bone cancer	0.00433	0.00445	CcSEcCtD
Perflutren—Tremor—Cisplatin—bone cancer	0.00431	0.00443	CcSEcCtD
Perflutren—Ill-defined disorder—Cisplatin—bone cancer	0.00427	0.00439	CcSEcCtD
Perflutren—Lymphadenopathy—Doxorubicin—bone cancer	0.00426	0.00437	CcSEcCtD
Perflutren—Hot flush—Epirubicin—bone cancer	0.0042	0.00431	CcSEcCtD
Perflutren—Menopausal symptoms—Epirubicin—bone cancer	0.00416	0.00427	CcSEcCtD
Perflutren—Malaise—Cisplatin—bone cancer	0.00415	0.00426	CcSEcCtD
Perflutren—Leukopenia—Cisplatin—bone cancer	0.00412	0.00423	CcSEcCtD
Perflutren—Anaphylactoid reaction—Epirubicin—bone cancer	0.00406	0.00416	CcSEcCtD
Perflutren—Cardiac failure congestive—Doxorubicin—bone cancer	0.004	0.00411	CcSEcCtD
Perflutren—Convulsion—Cisplatin—bone cancer	0.00399	0.0041	CcSEcCtD
Perflutren—Myalgia—Cisplatin—bone cancer	0.00392	0.00402	CcSEcCtD
Perflutren—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00389	0.004	CcSEcCtD
Perflutren—Hot flush—Doxorubicin—bone cancer	0.00388	0.00399	CcSEcCtD
Perflutren—Discomfort—Cisplatin—bone cancer	0.00387	0.00398	CcSEcCtD
Perflutren—Menopausal symptoms—Doxorubicin—bone cancer	0.00385	0.00395	CcSEcCtD
Perflutren—Face oedema—Epirubicin—bone cancer	0.00379	0.00389	CcSEcCtD
Perflutren—Oedema—Cisplatin—bone cancer	0.00376	0.00386	CcSEcCtD
Perflutren—Anaphylactic shock—Cisplatin—bone cancer	0.00376	0.00386	CcSEcCtD
Perflutren—Anaphylactoid reaction—Doxorubicin—bone cancer	0.00375	0.00385	CcSEcCtD
Perflutren—Cardiac arrest—Epirubicin—bone cancer	0.00373	0.00383	CcSEcCtD
Perflutren—Nervous system disorder—Cisplatin—bone cancer	0.00368	0.00378	CcSEcCtD
Perflutren—Tachycardia—Cisplatin—bone cancer	0.00367	0.00377	CcSEcCtD
Perflutren—Skin disorder—Cisplatin—bone cancer	0.00365	0.00375	CcSEcCtD
Perflutren—Hyperhidrosis—Cisplatin—bone cancer	0.00363	0.00373	CcSEcCtD
Perflutren—Dry skin—Epirubicin—bone cancer	0.0036	0.00369	CcSEcCtD
Perflutren—Eosinophilia—Methotrexate—bone cancer	0.00359	0.00369	CcSEcCtD
Perflutren—Hypotension—Cisplatin—bone cancer	0.00351	0.00361	CcSEcCtD
Perflutren—Face oedema—Doxorubicin—bone cancer	0.00351	0.0036	CcSEcCtD
Perflutren—Cardiac arrest—Doxorubicin—bone cancer	0.00345	0.00355	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00342	0.00351	CcSEcCtD
Perflutren—Paraesthesia—Cisplatin—bone cancer	0.00337	0.00346	CcSEcCtD
Perflutren—Eosinophilia—Epirubicin—bone cancer	0.00336	0.00345	CcSEcCtD
Perflutren—Dyspnoea—Cisplatin—bone cancer	0.00335	0.00344	CcSEcCtD
Perflutren—Dry skin—Doxorubicin—bone cancer	0.00333	0.00342	CcSEcCtD
Perflutren—Gastrointestinal disorder—Cisplatin—bone cancer	0.00324	0.00333	CcSEcCtD
Perflutren—Pain—Cisplatin—bone cancer	0.00321	0.0033	CcSEcCtD
Perflutren—Conjunctivitis—Methotrexate—bone cancer	0.00314	0.00323	CcSEcCtD
Perflutren—Eosinophilia—Doxorubicin—bone cancer	0.00311	0.00319	CcSEcCtD
Perflutren—Feeling abnormal—Cisplatin—bone cancer	0.0031	0.00318	CcSEcCtD
Perflutren—Body temperature increased—Cisplatin—bone cancer	0.00297	0.00305	CcSEcCtD
Perflutren—Neuropathy peripheral—Epirubicin—bone cancer	0.00297	0.00305	CcSEcCtD
Perflutren—Conjunctivitis—Epirubicin—bone cancer	0.00294	0.00302	CcSEcCtD
Perflutren—Haemoglobin—Methotrexate—bone cancer	0.00292	0.003	CcSEcCtD
Perflutren—Haemorrhage—Methotrexate—bone cancer	0.0029	0.00298	CcSEcCtD
Perflutren—Pharyngitis—Methotrexate—bone cancer	0.00288	0.00296	CcSEcCtD
Perflutren—Visual impairment—Methotrexate—bone cancer	0.0028	0.00287	CcSEcCtD
Perflutren—Hypersensitivity—Cisplatin—bone cancer	0.00277	0.00284	CcSEcCtD
Perflutren—Bradycardia—Epirubicin—bone cancer	0.00276	0.00284	CcSEcCtD
Perflutren—Neuropathy peripheral—Doxorubicin—bone cancer	0.00274	0.00282	CcSEcCtD
Perflutren—Haemoglobin—Epirubicin—bone cancer	0.00273	0.0028	CcSEcCtD
Perflutren—Rhinitis—Epirubicin—bone cancer	0.00272	0.0028	CcSEcCtD
Perflutren—Conjunctivitis—Doxorubicin—bone cancer	0.00272	0.00279	CcSEcCtD
Perflutren—Haemorrhage—Epirubicin—bone cancer	0.00272	0.00279	CcSEcCtD
Perflutren—Eye disorder—Methotrexate—bone cancer	0.00271	0.00278	CcSEcCtD
Perflutren—Tinnitus—Methotrexate—bone cancer	0.00271	0.00278	CcSEcCtD
Perflutren—Hypoaesthesia—Epirubicin—bone cancer	0.0027	0.00277	CcSEcCtD
Perflutren—Asthenia—Cisplatin—bone cancer	0.0027	0.00277	CcSEcCtD
Perflutren—Pharyngitis—Epirubicin—bone cancer	0.0027	0.00277	CcSEcCtD
Perflutren—Cardiac disorder—Methotrexate—bone cancer	0.00269	0.00277	CcSEcCtD
Perflutren—Connective tissue disorder—Epirubicin—bone cancer	0.00267	0.00274	CcSEcCtD
Perflutren—Angiopathy—Methotrexate—bone cancer	0.00263	0.0027	CcSEcCtD
Perflutren—Immune system disorder—Methotrexate—bone cancer	0.00262	0.00269	CcSEcCtD
Perflutren—Visual impairment—Epirubicin—bone cancer	0.00262	0.00269	CcSEcCtD
Perflutren—Mediastinal disorder—Methotrexate—bone cancer	0.00262	0.00269	CcSEcCtD
Perflutren—Chills—Methotrexate—bone cancer	0.0026	0.00267	CcSEcCtD
Perflutren—Diarrhoea—Cisplatin—bone cancer	0.00257	0.00264	CcSEcCtD
Perflutren—Bradycardia—Doxorubicin—bone cancer	0.00256	0.00263	CcSEcCtD
Perflutren—Eye disorder—Epirubicin—bone cancer	0.00254	0.00261	CcSEcCtD
Perflutren—Tinnitus—Epirubicin—bone cancer	0.00253	0.0026	CcSEcCtD
Perflutren—Erythema—Methotrexate—bone cancer	0.00253	0.00259	CcSEcCtD
Perflutren—Haemoglobin—Doxorubicin—bone cancer	0.00253	0.00259	CcSEcCtD
Perflutren—Flushing—Epirubicin—bone cancer	0.00252	0.00259	CcSEcCtD
Perflutren—Cardiac disorder—Epirubicin—bone cancer	0.00252	0.00259	CcSEcCtD
Perflutren—Rhinitis—Doxorubicin—bone cancer	0.00252	0.00259	CcSEcCtD
Perflutren—Haemorrhage—Doxorubicin—bone cancer	0.00251	0.00258	CcSEcCtD
Perflutren—Hypoaesthesia—Doxorubicin—bone cancer	0.0025	0.00257	CcSEcCtD
Perflutren—Pharyngitis—Doxorubicin—bone cancer	0.00249	0.00256	CcSEcCtD
Perflutren—Dysgeusia—Methotrexate—bone cancer	0.00247	0.00254	CcSEcCtD
Perflutren—Connective tissue disorder—Doxorubicin—bone cancer	0.00247	0.00254	CcSEcCtD
Perflutren—Angiopathy—Epirubicin—bone cancer	0.00246	0.00253	CcSEcCtD
Perflutren—Immune system disorder—Epirubicin—bone cancer	0.00245	0.00252	CcSEcCtD
Perflutren—Mediastinal disorder—Epirubicin—bone cancer	0.00245	0.00251	CcSEcCtD
Perflutren—Back pain—Methotrexate—bone cancer	0.00244	0.00251	CcSEcCtD
Perflutren—Chills—Epirubicin—bone cancer	0.00244	0.0025	CcSEcCtD
Perflutren—Arrhythmia—Epirubicin—bone cancer	0.00243	0.00249	CcSEcCtD
Perflutren—Visual impairment—Doxorubicin—bone cancer	0.00242	0.00249	CcSEcCtD
Perflutren—Vomiting—Cisplatin—bone cancer	0.00239	0.00245	CcSEcCtD
Perflutren—Vision blurred—Methotrexate—bone cancer	0.00238	0.00244	CcSEcCtD
Perflutren—Rash—Cisplatin—bone cancer	0.00237	0.00243	CcSEcCtD
Perflutren—Dermatitis—Cisplatin—bone cancer	0.00237	0.00243	CcSEcCtD
Perflutren—Erythema—Epirubicin—bone cancer	0.00236	0.00243	CcSEcCtD
Perflutren—Eye disorder—Doxorubicin—bone cancer	0.00235	0.00241	CcSEcCtD
Perflutren—Ill-defined disorder—Methotrexate—bone cancer	0.00234	0.00241	CcSEcCtD
Perflutren—Tinnitus—Doxorubicin—bone cancer	0.00234	0.00241	CcSEcCtD
Perflutren—Flushing—Doxorubicin—bone cancer	0.00233	0.00239	CcSEcCtD
Perflutren—Cardiac disorder—Doxorubicin—bone cancer	0.00233	0.00239	CcSEcCtD
Perflutren—Dysgeusia—Epirubicin—bone cancer	0.00231	0.00238	CcSEcCtD
Perflutren—Back pain—Epirubicin—bone cancer	0.00229	0.00235	CcSEcCtD
Perflutren—Angiopathy—Doxorubicin—bone cancer	0.00228	0.00234	CcSEcCtD
Perflutren—Malaise—Methotrexate—bone cancer	0.00228	0.00234	CcSEcCtD
Perflutren—Muscle spasms—Epirubicin—bone cancer	0.00227	0.00233	CcSEcCtD
Perflutren—Immune system disorder—Doxorubicin—bone cancer	0.00227	0.00233	CcSEcCtD
Perflutren—Vertigo—Methotrexate—bone cancer	0.00227	0.00233	CcSEcCtD
Perflutren—Mediastinal disorder—Doxorubicin—bone cancer	0.00226	0.00233	CcSEcCtD
Perflutren—Leukopenia—Methotrexate—bone cancer	0.00226	0.00232	CcSEcCtD
Perflutren—Chills—Doxorubicin—bone cancer	0.00225	0.00232	CcSEcCtD
Perflutren—Arrhythmia—Doxorubicin—bone cancer	0.00224	0.00231	CcSEcCtD
Perflutren—Nausea—Cisplatin—bone cancer	0.00223	0.00229	CcSEcCtD
Perflutren—Vision blurred—Epirubicin—bone cancer	0.00223	0.00229	CcSEcCtD
Perflutren—Cough—Methotrexate—bone cancer	0.0022	0.00226	CcSEcCtD
Perflutren—Ill-defined disorder—Epirubicin—bone cancer	0.00219	0.00225	CcSEcCtD
Perflutren—Convulsion—Methotrexate—bone cancer	0.00219	0.00225	CcSEcCtD
Perflutren—Erythema—Doxorubicin—bone cancer	0.00219	0.00225	CcSEcCtD
Perflutren—Agitation—Epirubicin—bone cancer	0.00217	0.00223	CcSEcCtD
Perflutren—Arthralgia—Methotrexate—bone cancer	0.00215	0.00221	CcSEcCtD
Perflutren—Myalgia—Methotrexate—bone cancer	0.00215	0.00221	CcSEcCtD
Perflutren—Chest pain—Methotrexate—bone cancer	0.00215	0.00221	CcSEcCtD
Perflutren—Dysgeusia—Doxorubicin—bone cancer	0.00214	0.0022	CcSEcCtD
Perflutren—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00214	0.00219	CcSEcCtD
Perflutren—Malaise—Epirubicin—bone cancer	0.00213	0.00219	CcSEcCtD
Perflutren—Discomfort—Methotrexate—bone cancer	0.00212	0.00218	CcSEcCtD
Perflutren—Vertigo—Epirubicin—bone cancer	0.00212	0.00218	CcSEcCtD
Perflutren—Syncope—Epirubicin—bone cancer	0.00212	0.00218	CcSEcCtD
Perflutren—Leukopenia—Epirubicin—bone cancer	0.00212	0.00217	CcSEcCtD
Perflutren—Back pain—Doxorubicin—bone cancer	0.00212	0.00217	CcSEcCtD
Perflutren—Muscle spasms—Doxorubicin—bone cancer	0.0021	0.00216	CcSEcCtD
Perflutren—Palpitations—Epirubicin—bone cancer	0.00209	0.00215	CcSEcCtD
Perflutren—Loss of consciousness—Epirubicin—bone cancer	0.00208	0.00213	CcSEcCtD
Perflutren—Cough—Epirubicin—bone cancer	0.00206	0.00212	CcSEcCtD
Perflutren—Anaphylactic shock—Methotrexate—bone cancer	0.00206	0.00212	CcSEcCtD
Perflutren—Vision blurred—Doxorubicin—bone cancer	0.00206	0.00212	CcSEcCtD
Perflutren—Convulsion—Epirubicin—bone cancer	0.00205	0.0021	CcSEcCtD
Perflutren—Hypertension—Epirubicin—bone cancer	0.00204	0.0021	CcSEcCtD
Perflutren—Ill-defined disorder—Doxorubicin—bone cancer	0.00203	0.00208	CcSEcCtD
Perflutren—Nervous system disorder—Methotrexate—bone cancer	0.00202	0.00208	CcSEcCtD
Perflutren—Arthralgia—Epirubicin—bone cancer	0.00201	0.00207	CcSEcCtD
Perflutren—Chest pain—Epirubicin—bone cancer	0.00201	0.00207	CcSEcCtD
Perflutren—Myalgia—Epirubicin—bone cancer	0.00201	0.00207	CcSEcCtD
Perflutren—Agitation—Doxorubicin—bone cancer	0.00201	0.00206	CcSEcCtD
Perflutren—Skin disorder—Methotrexate—bone cancer	0.002	0.00206	CcSEcCtD
Perflutren—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.002	0.00205	CcSEcCtD
Perflutren—Hyperhidrosis—Methotrexate—bone cancer	0.00199	0.00205	CcSEcCtD
Perflutren—Discomfort—Epirubicin—bone cancer	0.00199	0.00204	CcSEcCtD
Perflutren—Malaise—Doxorubicin—bone cancer	0.00197	0.00203	CcSEcCtD
Perflutren—Dry mouth—Epirubicin—bone cancer	0.00197	0.00202	CcSEcCtD
Perflutren—Vertigo—Doxorubicin—bone cancer	0.00197	0.00202	CcSEcCtD
Perflutren—Syncope—Doxorubicin—bone cancer	0.00196	0.00201	CcSEcCtD
Perflutren—Leukopenia—Doxorubicin—bone cancer	0.00196	0.00201	CcSEcCtD
Perflutren—Palpitations—Doxorubicin—bone cancer	0.00193	0.00198	CcSEcCtD
Perflutren—Oedema—Epirubicin—bone cancer	0.00193	0.00198	CcSEcCtD
Perflutren—Anaphylactic shock—Epirubicin—bone cancer	0.00193	0.00198	CcSEcCtD
Perflutren—Hypotension—Methotrexate—bone cancer	0.00193	0.00198	CcSEcCtD
Perflutren—Loss of consciousness—Doxorubicin—bone cancer	0.00192	0.00197	CcSEcCtD
Perflutren—Cough—Doxorubicin—bone cancer	0.00191	0.00196	CcSEcCtD
Perflutren—Shock—Epirubicin—bone cancer	0.0019	0.00195	CcSEcCtD
Perflutren—Convulsion—Doxorubicin—bone cancer	0.0019	0.00195	CcSEcCtD
Perflutren—Nervous system disorder—Epirubicin—bone cancer	0.00189	0.00194	CcSEcCtD
Perflutren—Hypertension—Doxorubicin—bone cancer	0.00189	0.00194	CcSEcCtD
Perflutren—Tachycardia—Epirubicin—bone cancer	0.00188	0.00193	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00188	0.00193	CcSEcCtD
Perflutren—Skin disorder—Epirubicin—bone cancer	0.00187	0.00192	CcSEcCtD
Perflutren—Hyperhidrosis—Epirubicin—bone cancer	0.00187	0.00192	CcSEcCtD
Perflutren—Chest pain—Doxorubicin—bone cancer	0.00186	0.00191	CcSEcCtD
Perflutren—Arthralgia—Doxorubicin—bone cancer	0.00186	0.00191	CcSEcCtD
Perflutren—Myalgia—Doxorubicin—bone cancer	0.00186	0.00191	CcSEcCtD
Perflutren—Paraesthesia—Methotrexate—bone cancer	0.00185	0.0019	CcSEcCtD
Perflutren—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00185	0.0019	CcSEcCtD
Perflutren—Discomfort—Doxorubicin—bone cancer	0.00184	0.00189	CcSEcCtD
Perflutren—Dyspnoea—Methotrexate—bone cancer	0.00184	0.00189	CcSEcCtD
Perflutren—Dry mouth—Doxorubicin—bone cancer	0.00182	0.00187	CcSEcCtD
Perflutren—Dyspepsia—Methotrexate—bone cancer	0.00181	0.00186	CcSEcCtD
Perflutren—Hypotension—Epirubicin—bone cancer	0.0018	0.00185	CcSEcCtD
Perflutren—Anaphylactic shock—Doxorubicin—bone cancer	0.00179	0.00183	CcSEcCtD
Perflutren—Oedema—Doxorubicin—bone cancer	0.00179	0.00183	CcSEcCtD
Perflutren—Gastrointestinal disorder—Methotrexate—bone cancer	0.00178	0.00183	CcSEcCtD
Perflutren—Fatigue—Methotrexate—bone cancer	0.00178	0.00183	CcSEcCtD
Perflutren—Pain—Methotrexate—bone cancer	0.00176	0.00181	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00176	0.00181	CcSEcCtD
Perflutren—Shock—Doxorubicin—bone cancer	0.00176	0.0018	CcSEcCtD
Perflutren—Nervous system disorder—Doxorubicin—bone cancer	0.00175	0.0018	CcSEcCtD
Perflutren—Tachycardia—Doxorubicin—bone cancer	0.00174	0.00179	CcSEcCtD
Perflutren—Skin disorder—Doxorubicin—bone cancer	0.00173	0.00178	CcSEcCtD
Perflutren—Paraesthesia—Epirubicin—bone cancer	0.00173	0.00178	CcSEcCtD
Perflutren—Hyperhidrosis—Doxorubicin—bone cancer	0.00173	0.00177	CcSEcCtD
Perflutren—Dyspnoea—Epirubicin—bone cancer	0.00172	0.00177	CcSEcCtD
Perflutren—Feeling abnormal—Methotrexate—bone cancer	0.0017	0.00174	CcSEcCtD
Perflutren—Dyspepsia—Epirubicin—bone cancer	0.0017	0.00174	CcSEcCtD
Perflutren—Gastrointestinal pain—Methotrexate—bone cancer	0.00169	0.00173	CcSEcCtD
Perflutren—Hypotension—Doxorubicin—bone cancer	0.00167	0.00171	CcSEcCtD
Perflutren—Gastrointestinal disorder—Epirubicin—bone cancer	0.00167	0.00171	CcSEcCtD
Perflutren—Fatigue—Epirubicin—bone cancer	0.00166	0.00171	CcSEcCtD
Perflutren—Pain—Epirubicin—bone cancer	0.00165	0.00169	CcSEcCtD
Perflutren—Urticaria—Methotrexate—bone cancer	0.00164	0.00168	CcSEcCtD
Perflutren—Abdominal pain—Methotrexate—bone cancer	0.00163	0.00167	CcSEcCtD
Perflutren—Body temperature increased—Methotrexate—bone cancer	0.00163	0.00167	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00163	0.00167	CcSEcCtD
Perflutren—Paraesthesia—Doxorubicin—bone cancer	0.0016	0.00165	CcSEcCtD
Perflutren—Dyspnoea—Doxorubicin—bone cancer	0.00159	0.00163	CcSEcCtD
Perflutren—Feeling abnormal—Epirubicin—bone cancer	0.00159	0.00163	CcSEcCtD
Perflutren—Gastrointestinal pain—Epirubicin—bone cancer	0.00158	0.00162	CcSEcCtD
Perflutren—Dyspepsia—Doxorubicin—bone cancer	0.00157	0.00161	CcSEcCtD
Perflutren—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00154	0.00158	CcSEcCtD
Perflutren—Fatigue—Doxorubicin—bone cancer	0.00154	0.00158	CcSEcCtD
Perflutren—Urticaria—Epirubicin—bone cancer	0.00153	0.00157	CcSEcCtD
Perflutren—Pain—Doxorubicin—bone cancer	0.00153	0.00157	CcSEcCtD
Perflutren—Body temperature increased—Epirubicin—bone cancer	0.00153	0.00157	CcSEcCtD
Perflutren—Abdominal pain—Epirubicin—bone cancer	0.00153	0.00157	CcSEcCtD
Perflutren—Hypersensitivity—Methotrexate—bone cancer	0.00152	0.00156	CcSEcCtD
Perflutren—Asthenia—Methotrexate—bone cancer	0.00148	0.00152	CcSEcCtD
Perflutren—Feeling abnormal—Doxorubicin—bone cancer	0.00147	0.00151	CcSEcCtD
Perflutren—Gastrointestinal pain—Doxorubicin—bone cancer	0.00146	0.0015	CcSEcCtD
Perflutren—Pruritus—Methotrexate—bone cancer	0.00146	0.0015	CcSEcCtD
Perflutren—Hypersensitivity—Epirubicin—bone cancer	0.00142	0.00146	CcSEcCtD
Perflutren—Urticaria—Doxorubicin—bone cancer	0.00142	0.00146	CcSEcCtD
Perflutren—Abdominal pain—Doxorubicin—bone cancer	0.00141	0.00145	CcSEcCtD
Perflutren—Body temperature increased—Doxorubicin—bone cancer	0.00141	0.00145	CcSEcCtD
Perflutren—Diarrhoea—Methotrexate—bone cancer	0.00141	0.00145	CcSEcCtD
Perflutren—Asthenia—Epirubicin—bone cancer	0.00138	0.00142	CcSEcCtD
Perflutren—Pruritus—Epirubicin—bone cancer	0.00136	0.0014	CcSEcCtD
Perflutren—Dizziness—Methotrexate—bone cancer	0.00136	0.0014	CcSEcCtD
Perflutren—Diarrhoea—Epirubicin—bone cancer	0.00132	0.00136	CcSEcCtD
Perflutren—Hypersensitivity—Doxorubicin—bone cancer	0.00132	0.00135	CcSEcCtD
Perflutren—Vomiting—Methotrexate—bone cancer	0.00131	0.00135	CcSEcCtD
Perflutren—Rash—Methotrexate—bone cancer	0.0013	0.00133	CcSEcCtD
Perflutren—Dermatitis—Methotrexate—bone cancer	0.0013	0.00133	CcSEcCtD
Perflutren—Headache—Methotrexate—bone cancer	0.00129	0.00133	CcSEcCtD
Perflutren—Asthenia—Doxorubicin—bone cancer	0.00128	0.00132	CcSEcCtD
Perflutren—Dizziness—Epirubicin—bone cancer	0.00128	0.00131	CcSEcCtD
Perflutren—Pruritus—Doxorubicin—bone cancer	0.00126	0.0013	CcSEcCtD
Perflutren—Vomiting—Epirubicin—bone cancer	0.00123	0.00126	CcSEcCtD
Perflutren—Nausea—Methotrexate—bone cancer	0.00122	0.00126	CcSEcCtD
Perflutren—Diarrhoea—Doxorubicin—bone cancer	0.00122	0.00125	CcSEcCtD
Perflutren—Rash—Epirubicin—bone cancer	0.00122	0.00125	CcSEcCtD
Perflutren—Dermatitis—Epirubicin—bone cancer	0.00122	0.00125	CcSEcCtD
Perflutren—Headache—Epirubicin—bone cancer	0.00121	0.00124	CcSEcCtD
Perflutren—Dizziness—Doxorubicin—bone cancer	0.00118	0.00121	CcSEcCtD
Perflutren—Nausea—Epirubicin—bone cancer	0.00115	0.00118	CcSEcCtD
Perflutren—Vomiting—Doxorubicin—bone cancer	0.00113	0.00117	CcSEcCtD
Perflutren—Rash—Doxorubicin—bone cancer	0.00113	0.00116	CcSEcCtD
Perflutren—Dermatitis—Doxorubicin—bone cancer	0.00112	0.00115	CcSEcCtD
Perflutren—Headache—Doxorubicin—bone cancer	0.00112	0.00115	CcSEcCtD
Perflutren—Nausea—Doxorubicin—bone cancer	0.00106	0.00109	CcSEcCtD
